Accéder au contenu
Merck
Toutes les photos(1)

Documents

B1110000

Bifonazole

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

1-(p,α-Diphenylbenzyl)imidazole

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C22H18N2
Numéro CAS:
Poids moléculaire :
310.39
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

bifonazole

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

c1ccc(cc1)C(c2ccc(cc2)-c3ccccc3)n4ccnc4

InChI

1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H

Clé InChI

OCAPBUJLXMYKEJ-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Bifonazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Bifonazole is an imidazole-based anti-fungal agent with broad spectrum activity against many fungi, molds, yeast and some Gram-positive bacteria. Bifonazole inhibits ergosterol biosynthetic protein 28 and Cytochrome P450 2B4.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Pictogrammes

Exclamation mark

Mention d'avertissement

Warning

Mentions de danger

Conseils de prudence

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Betty Wächtler et al.
Antimicrobial agents and chemotherapy, 55(9), 4436-4439 (2011-07-13)
Clotrimazole and bifonazole are highly effective antifungal agents against mucosal Candida albicans infections. Here we examined the effects of low levels of clotrimazole and bifonazole on the ability of C. albicans to adhere, invade, and damage vaginal epithelial cells. Although
Nehama Linder et al.
Birth defects research. Part A, Clinical and molecular teratology, 88(3), 201-204 (2009-12-17)
Neonatal limb reduction defects may be caused by exposure to an external agent. The azole derivatives are used in the treatment of systemic and dermal mycoses. Their relative teratogenic risk is still controversial. We describe two newborns with severe limb
Yonghong Zhao et al.
The Journal of biological chemistry, 281(9), 5973-5981 (2005-12-24)
To better understand ligand-induced structural transitions in cytochrome P450 2B4, protein-ligand interactions were investigated using a bulky inhibitor. Bifonazole, a broad spectrum antifungal agent, inhibits monooxygenase activity and induces a type II binding spectrum in 2B4dH(H226Y), a modified enzyme previously
Salomé El Hage et al.
Archiv der Pharmazie, 344(6), 402-410 (2011-03-25)
Two series of chlorinated benzhydryl imidazole and triazole derivatives were synthesized and tested in vitro against representative strains of potent pathogenic bacteria (Staphylococcus aureus CIP 4.83, Escherichia hirae CIP 5855, Pseudomonas aeruginosa CIP 82118, Escherichia coli CIP 53126) and fungi
M Arabatzis
Clinical and experimental dermatology, 37(4), 370-373 (2012-03-24)
This is a report, the first to my knowledge, of secondary nail-apparatus involvement by Aureobasidium pullulans in a patient with onycholysis related to hypothyroidism. Complete cure of the lesions was seen after 2 weeks of itraconazole and 2 months of

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique